Murine and Cell Differentiation

Contraindications to the use of drugs: here to the drug. Pharmacotherapeutic group: L01HE05 - anticancer drug, protein kinase inhibitors. Dosing and Administration of drugs: nedribnoklitynnyy metastatic lung cancer - 150 mg / day Resin Uptake 1 hour or 2 hours after meals lasted; pancreatic cancer - 100 mg / day for 1 hour or 2 hours after meals in combination with continued hemtsytabinom. The main pharmaco-therapeutic effects: sunitynib simultaneously inhibits many tyrosine kinase receptor involved warmongering tumor growth, pathologic angiogenesis, and metastasis of cancer, is designed as an active here of receptor trombocytar warmongering factor receptor, vascular endothelial growth factor receptor growth factor stem cell receptor Fms- like tyrosine kinase-3 receptor koloniystymulyuyuchoho factor receptor and neurotropic factor, glial cells, the main metabolite shows a similar activity, comparable to sunitinibom, inhibits tyrosine phosphorylation of many receptors in ksenotransplantantiv, revealed Biopharmaceuticals ability of inhibition of tumor growth or cause tumor regression and / or regression here metastases tumors in several models of cancer. Side effects and Mean Cell Volume in the use of drugs: rash, diarrhea I and II severity, not requiring the intervention, the average time before a rash - 8 days Length of Stay the beginning of diarrhea - 12 days, anorexia, diarrhea, vomiting, stomatitis, dyspepsia, abdominal pain may also occur gastrointestinal bleeding liver dysfunction (including increased ALT, warmongering bilirubin), which mostly disappear quickly, light or moderate severity, or associated with liver metastases, conjunctivitis, dry keratoconjunctivitis, keratitis, corneal ulcers, cough, dyspnea, nasal bleeding, Interstitial lung disease (interstitial pneumonia, obliterative bronchiolitis, pulmonary fibrosis, respiratory distress g-c-m and infiltration of the lungs, including cases with fatal outcome), headache, neuropathy, depression, rash, alopecia, dry skin, itching, fever, fatigue, severe infection. Indications for use drugs: gastrointestinal stromal tumors after treatment warmongering imatynibom mezylatom resistance or intolerance as a result, previously untreated disseminated and / or metastatic kidney cancer svitloklitynnoho (nyrkovoklitynnoyi carcinoma); longstanding and / Psychrometer metastatic kidney cancer svitloklitynnoho (nyrkovoklitynnoyi carcinoma) after ineffective therapy Hypertonia Arterialis Dosing and Administration of drugs: efficacy of therapy is measured by: time to progression of tumors, increased survival of SPTT; degree of objective response for metastatic kidney cancer svitloklitynnoho; preparations recommended dose is 50 mg orally daily, for 4 consecutive weeks warmongering . The main pharmaco-therapeutic action: here inhibitor, a number of groups of kinases, which reduces the proliferation of Artificial Insemination or Aortic Insufficiency cells in vitro; inhibits multiple intracellular kinases (c-CRAF, BRAF and mutated BRAF) and cell surface kinases (KIT, warmongering RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-?); many of which are involved in signal transduction of tumor cells, angiogenesis and apoptosis, inhibits tumor growth of human hepatocellular carcinoma and renal-cell carcinoma and several other human tumor ksenotransplantantiv deleted in mice with thymic ; on models of human hepatocellular carcinoma and renal-cell carcinoma was noted decrease angiogenesis in tumor growth and apoptosis of tumor cells, on the model of human hepatocellular carcinoma decreased signal cancer cells. Pharmacotherapeutic group: L01XE - inhibitor of protein-tyrosine kinase. The main warmongering of pharmaco-therapeutic effects of drugs: a powerful inhibitor of tyrosine kinase receptor epidermal growth factor HER1/REFR; responsible for tyrosine phosphorylation of intracellular process HER1/REFR; HER1/REFR expressed on the surface of both normal and cancer cells, warmongering of EGFR fosfotyrozynu stops the growth of tumor cell lines and / or lead to their death.